Doxycycline hyclate controlled release - POLYPID
Alternative Names: D-PLEX; D-PLEX-100; Doxycycline/polymer-lipid encapsulation matrix; PLEX-doxycyclineLatest Information Update: 10 Dec 2025
At a glance
- Originator POLYPID
- Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Surgical wound infections
Most Recent Events
- 03 Dec 2025 PolyPid held a Pre-NDA meeting with US FDA for NDA submission of Doxycycline hyclate controlled release in Surgical wound infections
- 12 Nov 2025 Doxycycline hyclate controlled release - POLYPID is available for licensing as of 12 Nov 2025
- 13 Aug 2025 Adverse events data from a phase III SHIELD II trial in Surgical wound infections released by POLYPID